Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%
How this was made
The 30-second read
Why it matters
Q2 results show pro forma gross margin and Adjusted EBITDA margin expansion, alongside operational efficiency improvements (turnaround time, DSO) and continued thyroid franchise growth, plus a planned CSO hire and ongoing pancreatic program development.
Market read
Traders can reassess near-term profitability trajectory and operational efficiency after the PancraGEN exit, while monitoring whether thyroid growth and cash collections stabilize.
What to watch
The pancreatic cancer program is not expected to contribute revenue in 2026 and remains un-cleared/ un-approved by FDA, so near-term valuation may still hinge on thyroid execution and working-capital trends.
Background
Interpace is now a thyroid-only molecular diagnostics company after discontinuing its PancraGEN pancreatic testing business in May 2025.
Ticker impact
Interpace reported Q2 2026 revenue of $9.1M and pro forma gross margin expansion to 62% after discontinuing PancraGEN in May 2025.
Near-term bias modestly positive on margin/efficiency progress, but limited upside unless investors see accelerating thyroid growth or clearer pancreatic program milestones.
The filing provides fresh quarterly financial datapoints (revenue, gross margin, operating income, Adjusted EBITDA) and operational KPIs (DSO, turnaround time, accounts/volume) plus a new CSO appointment and pancreatic program timeline expectations.
Market effects
Signals improving profitability potential for molecular diagnostics focused on thyroid testing, with operational leverage from lab automation.
No specific regional market linkage beyond US healthcare diagnostics demand.
Limited direct global read-through; primarily US-focused reimbursement and FDA clearance pathway.
Counterpoint
Revenue is essentially flat (Q2 $9.1M vs $9.2M prior year) and cash collections declined, so margin gains may not translate into sustained top-line momentum.
Key entities
- issuerInterpace Biosciences, Inc.
OTCQX-listed IDXG, reporting Q2 2026 thyroid-only molecular diagnostics results and business update.
- executiveChris McCarthy
CFO quoted on Q2 revenue, margin expansion, and lab automation scaling.
- executiveTom Burnell
CEO quoted on durability of transition and platform combination strategy.
- technology_platformThyGeNEXT and ThyraMIR v2
Interpace’s mutation detection and microRNA pathway insight platforms referenced as drivers of commercial execution.
